Daily Stock Analysis, CLLS, Cellectis SA, priceseries

Cellectis SA. Daily Stock Analysis
Stock Information
Open
9.83
Close
10.11
High
10.32
Low
9.73
Previous Close
9.73
Daily Price Gain
0.38
YTD High
20.84
YTD High Date
Apr 23, 2019
YTD Low
9.50
YTD Low Date
Oct 10, 2019
YTD Price Change
-7.06
YTD Gain
-41.12%
52 Week High
28.24
52 Week High Date
Oct 17, 2018
52 Week Low
9.50
52 Week Low Date
Oct 10, 2019
52 Week Price Change
-17.71
52 Week Gain
-63.66%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 31. 2017
18.24
Feb 23. 2017
21.56
16 Trading Days
18.20%
Link
LONG
Aug 22. 2017
24.23
Sep 5. 2017
26.42
9 Trading Days
9.06%
Link
LONG
Apr 1. 2019
18.57
Apr 24. 2019
19.96
16 Trading Days
7.48%
Link
Company Information
Stock Symbol
CLLS
Exchange
NasdaqGM
Company URL
http://www.cellectis.com
Company Phone
33181691600
CEO
André Choulika
Headquarters
-
Business Address
8 RUE DE LA CROIX JARRY, PARIS, LLE-DE-FRANCE, FRANCE 75013
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001627281
About

Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

Description

Developing cancer immunotherapies based on gene-edited CAR T-cells.